HIGHLIGHTS
- who: Giuseppe Ercolano from the University of Geneva, Geneva, Switzerland have published the research: PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS
- what: The authors characterize the expression and functional role of PPARγ in human and mouse ILCs to assess whether PPARγ can be targeted in the context of an ILC-directed immunotherapy. The authors demonstrate that PPARγ is selectively expressed in ILC2s, both in humans and mice. Lastly, by inducible and conditional deletion of PPARγ in ILCs using PPARgfl/flId2CreERT2 mice and a heterotypic tumor model . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.